Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Johnson & Johnson
  6. News
  7. Summary
    JNJ   US4781601046

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-06-29 pm EDT
176.99 USD   +0.03%
10:06aNHIF, Janssen Kenya Sign MOU to Enhance Prostrate Cancer Drugs Access
AQ
10:00aJohnson & Johnson Unit Secures FDA's Breakthrough Therapy Designation For Talquetamab in Multiple Myeloma
MT
06/28MeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Linked Retinitis Pigmentosa Patients
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Raymond James Adjusts Price Target on Johnson & Johnson to $196 From $195, Keeps Outperform Rating

04/20/2022 | 08:17am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about JOHNSON & JOHNSON
10:06aNHIF, Janssen Kenya Sign MOU to Enhance Prostrate Cancer Drugs Access
AQ
10:00aJohnson & Johnson Unit Secures FDA's Breakthrough Therapy Designation For Talquetamab i..
MT
06/28MeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Li..
MT
06/27Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Co..
AQ
06/24Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia D..
MT
06/24Johnson & Johnson's Unit Janssen Says EMA's Committee Backs Approval of Imbruvica to Tr..
MT
06/24JOHNSON & JOHNSON'S JANSSEN : CHMP Backs Expanded Imbruvica Use in Chronic Lymphocytic Leu..
DJ
06/23JOHNSON & JOHNSON : Renews Commitment to Fight Neglected Tropical Diseases, Investing in B..
PU
06/22WALL STREET STOCK EXCHANGE : Powell's tall order to reassure investors
06/22Daiwa Securities Starts Johnson & Johnson at Outperform With $180 Price Target
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 505 M - -
Net income 2022 22 521 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 20,6x
Yield 2022 2,52%
Capitalization 466 B 466 B -
EV / Sales 2022 4,73x
EV / Sales 2023 4,45x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 176,94 $
Average target price 187,28 $
Spread / Average Target 5,84%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON6.46%465 600
ELI LILLY AND COMPANY18.48%285 909
PFIZER, INC.-12.14%284 248
ROCHE HOLDING AG-16.24%270 886
ABBVIE INC.12.62%269 467
NOVO NORDISK A/S5.31%248 487